摘要
一、概述与定义
临床症状的缓解一直是克罗恩病治疗所追求的目标。但是大量研究证实，短期内临床症状的缓解并不能改善克罗恩病长期的自然病程，包括手术率及住院率在内的长期预后指标并不能得到显著改善。
出处
《中华外科杂志》
CAS
CSCD
北大核心
2012年第12期1139-1142,共4页
Chinese Journal of Surgery
基金
江苏省自然科学基金创新学者攀登项目资助项目（BK2010017）
江苏省“333高层次人才培养工程”资助项目（BRA2011232）
参考文献47
-
1Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn' s disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology, 1996, 110: 45-51.
-
2CosnesJ, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn' s disease on the need for intestinal surgery. Gut, 2005, 54: 237 -241.
-
3D'Haens GR, Fedorak R, Lemann M, et al. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis, 2009, 15: 1599-1604.
-
4De Cruz P, Kamm MA, Prideaux L, et al. Mucosal healing in Crohn's disease: a systematic review [published online ahead of print April 26, 2012]. Inflamm Bowel Dis, 2012: http:// onlinelibrary. wiley. com/doi/IO. 1002/ibd. 22977/abstract? systemMessage = Wiley + Online + Library + will + be + disrupted + on + 25 + August + from + 13% 3AOO-15% 3AOO + BST + % 2808% 3AOO-IO% 3AOO + EDT% 29 + for + essential + maintenance.
-
5Dave M, Loftus EVJr. Mucosal healing in inflammatory bowel disease-a true paradigm of success? Gastroenterol Hepatol (N Y) , 2012,8: 29-38.
-
6Modigliani R, MaryJY, SimonJF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d' Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology, 1990, 98: 811-818.
-
7Mantzaris GJ, Christidou A, Sfakianakis M, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn' s disease. Inflamm Bowel Dis, 2009, 15: 375-382.
-
8ColombelJF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N EnglJ Med, 2010, 362: 1383-1395.
-
9Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology, 2012, 142: 1102-111 I.
-
10ColombelJF, Lemann M, Allez M, et al. Predictors of endoscopic response and remission in patients with active Crohn's disease treated with certolizumab pegol , a logistic regression analysis of the music data. Gastroenterology, 2009, 136: A 181.
同被引文献16
-
1Bemstein CN,Wajda A,Svenson LW,et al. The epidemiology of inflammatory bowel disease in Canada:a population-based study [J]. The American Journal of Gastroenterology,2006,101 (7): 1559-1568.
-
2Ahuja V ,Tandon RK. Inflammatory bowel disease in the Asia - Pacific area:a comparison with developed countries and regional differences[J]. Journal of Digestive Diseases,2010,11 (3) : 134-147.
-
3Travis SPL, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management[J]. Gut,2006,55(Suppl 1):16-35.
-
4Lichtenstein GR,Hanauer SB,Sandbom WJ. Management of Crohn's disease in adults [J]. The American Journal of Gastroenterology, 2009,104(2) :465-483.
-
5Hanauer SB, Feagan BG, Liehtenstein GR, et al. Maintenance in- fliximab for Crohn's disease:the ACCENTI randomised trial[J]. The Lancet,2002,359(9317) : 1541-1549.
-
6Present DH, Rutgeerts P,Targan S,et al. Infliximab for the treat- ment of fistulas in patients with Crohn's disease[J]. New England Journal of Medicine, 1999,340 ( 18 ) : 1398-1405.
-
7Sands BE ,Anderson FH,Bernstein CN,et al. Infliximab mainte- nance therapy for fistulizing Crohn's disease [J]. New England Journal of Medicine, 2004,350 (9) : 876-885.
-
8De Chambrun GP,Peyrin-Biroulet L,Lemann M,et al. Clinical implications of mucosal healing for the management of IBD [J]. Nature Reviews Gastroenterology and Hepatology ,2009,7 ( 1 ) : 15- 29.
-
9Colombel JF,Sandborn WJ,Reiniseh W,et al. Infliximab,azathio- prine,or combination therapy for Crohn's disease[J]. New England Journal of Medicine,2010,362(15) : 1383-1395.
-
10Rutgeerts P, Feagan BG, Lichtenstein GR,et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn' s disease[J]. Gastroenterology, 2004,126 (2) : 402-413.
-
1聂胜利,吴军辉,张庆芳.英夫利昔单抗治疗炎症性肠病的疗效及影响因素分析[J].中国实用医药,2015,10(5):13-14. 被引量：4
-
2邱云,郑青,冉志华.黏膜愈合在炎症性肠病中的临床应用[J].胃肠病学,2011,16(2):109-111. 被引量：1
-
3黎莉,杨卫文,谭松,刘正勇,何天兰,戴振媛.溃疡性结肠炎患者外周血及结肠黏膜TNF-a、IL-6和IL-2变化的临床意义[J].中国现代医学杂志,2016,26(14):42-47. 被引量：33
-
4王冬,张晓岚.内镜在炎症性肠病中的作用[J].临床荟萃,2016,31(8):852-856. 被引量：3
-
5马日孜亚木.马合么麦特.康复新液治疗胃食管反流病的疗效观察[J].中国医药指南,2013,11(27):16-17.
-
6卢英军.埃索美拉唑联合莫沙必利治疗胃食管反流病临床效果分析[J].河北医药,2012,34(12):1788-1789. 被引量：22
-
7程海涛,黄玉筑,方念.英夫利昔单抗在溃疡性结肠炎中的应用[J].实用中西医结合临床,2014,14(11):59-60. 被引量：5
-
8范建高,葛文松.重视炎症性肠病的规范化治疗[J].中华消化病与影像杂志（电子版）,2014,4(3):1-3.
-
9谢兰,刘杰,姚勇.英夫利昔治疗炎症性肠病的疗效观察[J].世界中医药,2016,11(B03):1192-1193. 被引量：1
-
10张恩,王勇.埃索美拉唑治疗胃食管反流病的临床疗效评估[J].中国民康医学,2013,25(16):24-24. 被引量：3
